Entry inhibitor combination shows promise.
D019380:Anti-HIV Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016860:CD4 Immunoadhesins / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology*; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016860:CD4 Immunoadhesins; C096753:CD4-IgG(2); D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide; C420063:leronlimab